The shoulder has been there for nine months. You did the physical therapy, you took the rest weeks, you have the MRI report in a drawer, and it is still the thing you think about when you reach for something on a high shelf. So at some point you typed a peptide name into a search bar, and somewhere in the results was a two-compound blend that everyone calls the Wolverine stack.

What you probably found next was not helpful. Half the pages selling it carry a laboratory disclaimer and address you as though you ran a research facility. The other half promise you a healing factor. Neither of those tells you the two things you actually need: what the science says, stated at its real strength, and what has to happen before a licensed clinician would consider prescribing anything.

This article is the first part. The evidence for BPC-157 and TB-500 is genuinely interesting, and it is also mostly from animals, and the specific combination the two are sold in has never been studied as a combination. All three of those statements are true at the same time, and any page that gives you only one of them is selling you something.

What is the Wolverine peptide stack?

The Wolverine stack is two peptides used together: BPC-157 and TB-500. That is the whole definition. There is no third ingredient and no proprietary anything — the name describes a pairing, not a formula owned by a manufacturer.

The nickname comes from the comic-book character with the famous rapid-healing ability. It was coined by people writing about the compounds, not by researchers publishing on them, and it is worth knowing that the name is marketing shorthand rather than a description of a measured effect. Nothing in the literature calls it that.

At Promise, "Wolverine" is a compounded prescription medication — the two peptides combined in a single vial at a fixed ratio by a licensed U.S. compounding pharmacy, dispensed only after a licensed provider reviews your request. It is not a supplement, and it is not sold over the counter. More on how that evaluation works further down.

Here is the honest summary before the detail, because it should frame everything after it:

  • BPC-157 has a real preclinical literature — meaningful animal data on tendon, muscle, bone and gut injury models, plus a well-characterized set of mechanisms. Human data amounts to three small pilot trials.
  • TB-500 is derived from a protein your body already makes. Its parent molecule has animal data on muscle and skin repair and, unusually for this category, two Phase 2 human trials in wound healing.
  • The combination has never been studied as a combination. Every "together they do X" statement you will read anywhere, including in this article, is a hypothesis built from the two separate literatures. It is a reasonable hypothesis. It is not a finding.
  • Neither compound is FDA-approved for musculoskeletal use, or for any of the uses discussed here.

What is BPC-157?

BPC-157 stands for Body Protection Compound-157. It is a pentadecapeptide — a chain of 15 amino acids — that corresponds to a partial sequence of a larger protective protein found naturally in human gastric juice. That origin is why the digestive research came first, and why the name is what it is: the parent protein was characterized for its protective effect on the stomach lining.

The compound sold today is a synthetic version of that fragment. The version in the published rodent literature is usually written "BPC 157" and described as a stable gastric pentadecapeptide.

What the animal research measured

The single most useful study to understand, because it shows what "the research" concretely means, is a 2006 rat experiment published in the Journal of Orthopaedic Research (Krivic et al.). Researchers detached the Achilles tendon from the calcaneus in male Wistar rats, then gave BPC 157 intraperitoneally at three doses spanning three orders of magnitude — 10 µg/kg, 10 ng/kg and 10 pg/kg of body weight — against a control group receiving 5 mL/kg of 0.9% saline. A separate arm received 1 mg/kg of 6α-methylprednisolone, a corticosteroid known to impair tendon healing, to test whether BPC 157 could counter that impairment. Dosing began within the first 30 minutes after surgery and continued until 24 hours before analysis.

They assessed the animals at days 1, 4, 7, 10, 14 and 21 on three kinds of endpoint: functional (the Achilles functional index), biomechanical (load to failure, stiffness, and Young's elasticity modulus), and histological (collagen fiber organization and type I collagen expression). In that model, the treated animals showed improved tendon-to-bone healing across those measures, and the corticosteroid-induced impairment was opposed.

Two things to take from that. First, this is what a real dataset in this field looks like — a specific species, a specific injury, a specific route, and endpoints you can measure with an instrument. Second, note the dose units. They are per kilogram of body weight, and the largest of them is micrograms. This matters when we get to the dosing numbers circulating online.

The systematic review

In 2025, a group at HSS published a systematic review of BPC-157 in orthopaedic sports medicine in the HSS Journal (Vasireddi et al.). They searched from database inception through June 3, 2024 and included 36 studies — 35 preclinical and 1 clinical.

Their finding, in their own framing, is that BPC-157 improved functional, structural, and biomechanical outcomes across models of fracture healing, tendon rupture, ligament tear and muscle injury. That is a fair and careful statement, and it is worth noticing how much weaker it is than the "confirmed consistent effects" language you will see attributed to this same review elsewhere. The authors themselves emphasize the lack of robust clinical safety data in humans.

The one clinical study in that set is worth naming precisely, because it is the only human orthopaedic datum in this entire article: a retrospective series of 12 patients who received intra-articular BPC-157 for chronic knee pain. Seven of the twelve reported relief, and that relief was reported as lasting more than six months. That is 12 people, looked at after the fact, with no control group, no blinding and no randomization. It is a reason to run a trial. It is not a result you can plan around.

Why BPC-157 is associated with gut health

Because that is where it started. The parent compound was identified for its protective effects in the gastrointestinal tract, and BPC-157 has since been examined in preclinical models of inflammatory bowel disease, ulcers and intestinal injury. A 2018 review in Current Pharmaceutical Design (Seiwerth et al.) frames the whole body of work exactly that way — gastrointestinal tract healing, with lessons carried across to tendon, ligament, muscle and bone.

These are animal models of those conditions. Nothing here establishes that BPC-157 treats inflammatory bowel disease or ulcers in people, and no regulator has evaluated it for that. Note also that this is a BPC-157 story specifically — TB-500 is not primarily studied for gut applications, so the gut research does not transfer to the blend as a whole.

What is TB-500?

TB-500 is a synthetic peptide fragment derived from thymosin beta-4 (Tβ4). That precision is deliberate: TB-500 is often described as "synthetic thymosin beta-4," but the 2026 orthopaedics review in JAAOS Global Research & Reviews (Rahman, Lee and Seeds) defines it as a fragment derived from the parent molecule, not the whole thing.

Unlike BPC-157, where the "157" points at a specific sequence, the "500" in TB-500 is just a compound designation. It does not encode a dose, a length, or a potency, and it is worth knowing that because the number gets read as meaningful more often than it should be.

Thymosin beta-4 is not exotic. Your body produces it in essentially every cell type except red blood cells, and its expression is upregulated in response to tissue injury — meaning it is part of the repair response you already run. It has a role in how cells move, grow and differentiate.

The primary mechanism: actin

Tβ4 is the major G-actin-sequestering protein in cells. Actin is the structural protein that gives a cell its shape and lets it crawl; by binding free actin monomers, Tβ4 influences cell shape, migration and division. Those three processes are, at a cellular level, most of what tissue repair consists of — cells have to move to the damage and then divide there.

The muscle research

A 2011 mouse study in the Journal of Biochemistry (Tokura et al.) is the cleanest piece of evidence connecting Tβ4 to muscle. The researchers showed that muscle injury increases local Tβ4 production, and that Tβ4 acts as a chemoattractant for myoblasts — the precursor cells that fuse to rebuild damaged muscle fibers. In other words, injured muscle releases Tβ4, and Tβ4 calls repair cells toward it.

The specifics: work was done in C57BL mice, using both the C2C12 myoblast line and primary myoblasts and myocytes derived from adult mouse satellite cells. Both native and sulphoxized forms of Tβ4 were chemotactically active. Tβ4 mRNA — along with Tβ10 mRNA — was upregulated in the early stage of regenerating muscle fibers.

Worth flagging what this study does not show: it is a chemotaxis and expression finding in mice and mouse-derived cells, not a demonstration that injecting TB-500 makes a human muscle injury resolve faster. And there is no hypertrophy data here or anywhere in this literature. TB-500 is sometimes marketed for muscle growth; that claim has no support in the cited research.

The skin research — and the human trials

The most substantive Tβ4 paper in this set is a 2012 review in the Annals of the New York Academy of Sciences (Treadwell et al.) on dermal healing. It covers full-thickness punch wounds across four animal model types — normal rats and mice, steroid-treated rats, diabetic mice, and aged mice — and reports that Tβ4 accelerated the rate of dermal repair in those models. The mechanisms it names are cell migration, stem-cell mobilization and differentiation, and inhibition of inflammation, apoptosis and infection.

It also contains something the peptide-marketing internet almost never mentions: two Phase 2 clinical trials in humans, in stasis ulcers and pressure ulcers. Among patients whose wounds did heal, healing occurred roughly a month faster. Read that conditional carefully — the acceleration applies to the patients who healed, not to everyone enrolled. Even so, this is real Phase 2 human wound-healing data, and it is the strongest human evidence anywhere in the Wolverine story.

One correction while we are here, because it circulates constantly: this paper is frequently cited as evidence for TB-500 in cardiac tissue repair and skeletal muscle regeneration. It contains neither. It is a dermal paper. Cardiac Tβ4 work does exist in the wider literature, but it is a different set of papers, and a page that cites the dermal review for cardiac claims has not read it.

Why combine BPC-157 and TB-500?

The rationale for the pairing is that the two compounds act through different pathways, so combining them is not redundant.

  • BPC-157 is primarily an angiogenic and growth-factor story — building and modulating blood supply into damaged tissue.
  • TB-500 is primarily a cytoskeletal and cell-trafficking story — actin binding, cell migration, and dampening the inflammatory response.

Put in plain terms, the hypothesis is a division of labor: BPC-157 builds the road into the injury site, TB-500 sends the repair crews down it. It is a genuinely sensible pairing on paper, and the two literatures do not overlap much, which is exactly why someone thought to combine them.

The limitation that governs everything else

There is no research on the combination. Not "limited research" — none. No study has administered BPC-157 and TB-500 together and measured what happens compared to either alone. Every synergy claim about this stack, including the road-and-crew framing two paragraphs up, is inference from two separate bodies of work.

That has a practical consequence: nobody can tell you that the pair outperforms either compound by itself, because nobody has measured it. A provider who prescribes the blend is making a clinical judgment about a plausible combination, not applying a trial result.

This is also the limitation that makes the rest of the evidence defensible. A page willing to say "the combination is untested" has earned the right to describe the individual mechanisms in detail.

How the mechanisms actually work

This section is the technical one. Skip to the next heading if you want the practical answers.

BPC-157: two routes to new blood vessels

BPC-157's angiogenic effect runs through at least two distinguishable pathways.

The VEGF-dependent route. BPC-157 upregulates VEGFR2 — the main receptor for vascular endothelial growth factor — and activates the VEGFR2 → Akt → eNOS signaling axis. The mechanistic work here is Hsieh et al., 2017, in the Journal of Molecular Medicine, which showed the activation is time-dependent and added the step most summaries leave out: BPC 157 promotes VEGFR2 internalization in vascular endothelial cells, and that internalization is blocked by dynasore, an endocytosis inhibitor. Enhanced vascular VEGFR2 expression was confirmed in rats.

The VEGF-independent route. BPC-157 also activates a Src → Caveolin-1 → eNOS pathway that produces nitric oxide without going through VEGF at all. Hsieh et al., 2020, in Scientific Reports worked in isolated rat aorta and found concentration- and NO-dependent effects on vasomotor tone. BPC 157 increased phosphorylation of Src, caveolin-1 and eNOS; a Src inhibitor abolished that, placing Src upstream; and co-immunoprecipitation showed BPC 157 reduces the binding between caveolin-1 and eNOS. That last detail is the elegant part — caveolin-1 normally holds eNOS in an inactive state, so loosening that grip releases the enzyme to make nitric oxide.

Net effect across both routes: new vessel formation plus modulation of vessel tone. A 2014 review in Current Pharmaceutical Design (Seiwerth et al.) describes BPC 157 as "the most potent angiomodulatory agent, acting through different vasoactive pathways and systems (e.g. NO, VEGF, FAK)" — note angiomodulatory, meaning it modulates the vascular response rather than simply increasing it. That characterization is the review authors' own, and it is fair to know that this research group has authored a large share of the favorable BPC-157 literature; independent replication is thinner than the citation count suggests.

Growth factors. Growth factors are the chemical messengers that tell cells when and how to grow, divide and specialize. The 2018 review compares BPC 157 directly against the standard angiogenic growth factors — EGF, FGF and VEGF — and reports that in its models, only BPC 157 was consistently effective across the full range of acute and chronic injury models tested.

Additional pathways. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine (McGuire et al.) adds ERK1/2 signaling, effects on fibroblast activity, endothelial and muscle repair, neuromuscular stabilization, and anti-inflammatory effects, and identifies the VEGFR2 and nitric oxide pathways as the key drivers.

A nuance on nitric oxide. A 2025 commentary in Pharmaceuticals (Sikiric et al.) makes a point that gets flattened in most retellings: BPC 157's effect on nitric oxide is bidirectional — raising it in some contexts, lowering it in others — always alongside counteraction of free-radical formation. The claim is regulation of the NO system, not simple NO elevation. That commentary is a defense of BPC-157 against prior criticism rather than original research, which is useful context for how to weigh it.

TB-500: cells on the move

TB-500's mechanism is the actin story above, expressed at tissue level: influence cell shape and mobility, and you influence how repair cells reach and populate damaged tissue. The muscle chemotaxis finding and the dermal migration and stem-cell mobilization findings are two views of the same underlying action.

TB-500 is also widely described as anti-inflammatory through cytokine modulation. The dermal review does report inhibition of inflammation as one of Tβ4's effects, so the direction is supported; a specific cytokine mechanism for TB-500 in humans is not something the cited literature establishes.

One claim to discard. You will read almost everywhere that TB-500's molecular structure lets it "travel easily through tissues," so it does not stay at the injection site and can reach injuries anywhere in the body. This is the single most repeated claim in peptide marketing and it is supported by nothing. No pharmacokinetic study is cited for it, no molecular weight is given, no distribution data is offered. Treat it as folklore until someone produces the study. For the same reason, be skeptical of anything you read about either compound's half-life — no half-life value for either peptide appears in the sources reviewed here.

The shared pathway map

The 2026 JAAOS review is the only source that treats BPC-157, TB-500 and GHK-Cu together, and it names the pathway superset that wound-healing peptides as a class are proposed to work through: PI3K/Akt, mTOR, MAPK, TGF-β, AMPK, IGF-1, BDNF, and HGF/c-Met. The mechanisms it names are angiogenesis, integrin-mediated extracellular matrix remodeling, fibroblast activation, and progenitor cell recruitment. Its conclusion is blunt and worth quoting in substance: preclinical studies are promising, there is a current lack of clinical trials, and these agents are not FDA-approved for musculoskeletal indications.

Which tissues has the research covered?

Four areas, with honestly different amounts of evidence behind each:

Tendon and ligament. The best-supported connective-tissue evidence. The rat Achilles model gives biomechanical and histological endpoints; the systematic review aggregates tendon rupture and ligament tear models. All preclinical.

Muscle. Supported for recovery — the myoblast chemotaxis work for Tβ4, and muscle injury models within the BPC-157 review set. Not supported for growth or hypertrophy, which no cited study measured.

Joints. The thinnest of the four. The only joint-specific datum in this evidence set is the 12-patient retrospective knee series described earlier. Cartilage and joint applications are an area of interest, not an area of demonstrated effect.

Skin and wound healing. Strong for Tβ4, and the only place with Phase 2 human data — the four animal models plus the two ulcer trials.

Vascular. BPC-157's blood-vessel effects are well characterized preclinically, including protection against certain kinds of vascular damage. TB-500's cardioprotective reputation, by contrast, rests on papers that are usually not the ones cited for it.

Does it affect the quality of repair, or just the speed?

This is a better question than most people ask, and the research does address it. Healing that goes badly produces scar tissue, and scar tissue does not have the mechanical or functional properties of the tissue it replaces — a repaired tendon that is mostly disorganized collagen is weaker than one that rebuilt properly.

The rat Achilles study measured exactly this. Alongside speed-type endpoints it assessed collagen fiber organization and type I collagen expression — structural quality — and biomechanical strength through load to failure, stiffness and Young's modulus. So the outcomes measured in preclinical models did include tissue quality, not only rate. Whether that carries into human tendon is untested.

Wolverine versus taking BPC-157 or TB-500 on its own

A provider might reasonably prescribe one compound rather than the blend. The reasoning is the same one researchers use when they run single-compound studies: if the target is narrow, or if you want to know which compound is doing what, a single agent is cleaner. A localized skin wound and a tendon-to-bone problem are not the same brief.

Mechanistically, the difference is additive: BPC-157 alone brings angiogenesis and growth-factor modulation. Adding TB-500 brings actin binding, cell migration and an additional anti-inflammatory route. The blend is proposed for complex injuries that span more than one tissue type — again, proposed, not demonstrated.

There is also a formulation argument, and it is the most concrete advantage the blend actually has. A pre-mixed vial holds the two compounds at a consistent ratio, prepared by the pharmacy. You are not combining anything yourself, and the ratio does not drift between doses.

For a deeper treatment of how the two compounds differ on their own, see our BPC-157 vs TB-500 comparison.

Wolverine versus KLOW

KLOW is the four-peptide blend: BPC-157, GHK-Cu, KPV, and TB-500. It takes the Wolverine pair and adds a copper peptide (GHK-Cu) and a tripeptide (KPV). The 2026 JAAOS review is the source that discusses GHK-Cu alongside BPC-157 and TB-500 as therapeutic peptides in orthopaedics.

The trade-off is straightforward and applies to every expanded blend: more compounds means more proposed pathways engaged, and also more variables. If four things are happening at once, attributing a change to any one of them — or knowing which component to adjust — gets harder. That is a real consideration for you and your provider, not just a research-design footnote. Which of the two blends fits, if either does, is a clinical question.

Both blends sit in the Muscle & Recovery area of the catalog, alongside TB-500 on its own.

What this looks like as a patient

Here is the part the research-use-only pages never answer.

Do I need a prescription? Who decides?

Yes, and a licensed provider does. Promise is a telehealth platform. You submit an intake, and a licensed provider in the prescriber network reviews every request — your history, your medications, what is actually going on with the injury. Not everyone qualifies, and a provider declining is a normal outcome, not a system failure.

That gate is the entire difference. Someone with a medical license and a duty to you is deciding.

Is it compounded? By whom?

Yes. Wolverine is prepared by PerfectRx, a licensed U.S. compounding pharmacy, and dispensed against your specific prescription. Compounded medications are made by a pharmacy for an individual patient; they are not mass-manufactured, and they are not FDA-approved products.

That last point deserves to be stated flatly rather than buried. Neither BPC-157 nor TB-500 is approved by the FDA for musculoskeletal use or for any of the applications discussed here. Both the 2026 JAAOS review and the 2025 narrative review say so directly, and the narrative review's own conclusion is that BPC-157 "should be considered investigational" — precisely because it is so widely available through unregulated sources. Anyone telling you otherwise is either uninformed or selling.

What about dosing?

Dosing is a decision for your prescribing provider and the pharmacy, and this article will not give you a number.

That is not squeamishness. Research doses vary by species, injury model, route and the outcome being measured — and the per-injection figures circulating on forums and vendor pages do not come from studies at all. They are typically presented as "typical animal-study doses," stated as flat amounts with no body-weight scaling, no route and no species, and no citation attached. Compare that to the doses in the rat Achilles study above: 10 µg/kg, 10 ng/kg and 10 pg/kg, scaled to body weight, given intraperitoneally. The circulating numbers sit several orders of magnitude away from what the animal literature actually administered. They are not a translation of the research; they are folklore that acquired a decimal point.

A provider setting a dose is working from your situation, the pharmacy's formulation, and clinical judgment. That is a different exercise from copying a number off a forum.

How is it given, and for how long?

These peptides are administered by injection — subcutaneous or intramuscular — following your provider's instructions. Oral BPC-157 has been studied, and its bioavailability by that route remains unresolved; nobody should tell you the oral form is equivalent, because that has not been established.

On duration: in the research literature, acute injury models typically run days to weeks, while chronic-condition work extends into months. Acute wound-healing studies have shown observable changes within days; tendon and ligament work runs weeks to months — the rat Achilles study, for reference, assessed animals from day 1 out to day 21. Different tissues repair at different natural rates, and connective tissue is slow. What that means for any individual course is your provider's call, not a schedule you can read off a study.

Storage and handling

Peptides are typically supplied as lyophilized (freeze-dried) powder and kept cool until reconstitution. Once reconstituted, refrigeration is generally necessary. Your pharmacy handles the preparation and reconstitution details and will tell you exactly how to store what you receive — this is not something to improvise from general internet guidance.

Follow the sterile technique your provider demonstrates, and dispose of needles in an approved sharps container. It is also genuinely useful to track your symptoms and response over time and bring that record to your follow-up. In the lab, careful record-keeping is what makes a result interpretable; the patient version does the same job for your provider.

Does quality matter?

A great deal. Contaminated or degraded peptide gives inconsistent results — that is true in a laboratory and it is true in a person. In research settings this is handled through purity standards; in a prescription setting it is handled by using a licensed compounding pharmacy operating under state and federal pharmacy regulation, dispensing against a prescription written for you.

This is the honest answer to the "where do I get quality peptides" question. Not a supplier with a certificate of analysis you cannot verify — a licensed pharmacy in a regulated chain of custody, reached through a provider.

What does it cost, and can I get it where I live?

Current pricing is shown on the Wolverine product page — it is a monthly subscription, and the price is the same whether you are in Phoenix or Providence. Promise's prescriber network is licensed in all 50 U.S. states and Washington, D.C., though not every treatment is available in every state. Your intake captures your state, and the provider review accounts for it.

What we still do not know

The gaps here are not small, and they are the reason this article reads the way it does.

  • Most of the evidence is from animal models. Translating rodent findings to humans requires care about physiological differences, and this literature has not made that jump.
  • The combination is untested. No trial has evaluated BPC-157 plus TB-500 as a pair.
  • Human data is minimal. Three pilot trials for BPC-157 total — chronic knee pain, interstitial cystitis, and an intravenous safety and pharmacokinetics study. No adverse effects were reported in them, which is reassuring as far as it goes, and the authors are explicit that the data remain too limited to draw conclusions from. The rigorous, large-scale trials simply do not exist yet.
  • Long-term effects are unknown, as are optimal dosing across applications and interactions with other compounds.
  • Interaction data does not exist. You will see it claimed that no contraindications have been identified for combining these peptides with others. That is absence of evidence being passed off as evidence of safety. The accurate statement is that combination interactions have not been studied, which is exactly why the decision belongs to a provider who knows your full medication list.

If you are considering it

The reasonable next step is a conversation. Bring your injury history, your imaging if you have it, your current medications, and what you have already tried. A provider will tell you whether peptide therapy is a sensible thing to try in your case, whether a different approach makes more sense first, or whether the answer is no.

This article is for general education and is not medical advice. It does not diagnose any condition or recommend any treatment, and it is not a substitute for a consultation with a licensed clinician. Every Promise request is reviewed by a licensed provider. Talk to your own healthcare provider about your specific situation, especially if you take other medications or have an existing medical condition.

References

  1. Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research. 2006;24(5):982-989. https://pubmed.ncbi.nlm.nih.gov/16583442/
  2. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal. 2025. https://pubmed.ncbi.nlm.nih.gov/40756949/
  3. Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Current Pharmaceutical Design. 2018;24(18):1972-1989. https://pubmed.ncbi.nlm.nih.gov/29998800/
  4. Rahman OF, Lee SJ, Seeds WA. Therapeutic peptides in orthopaedics: applications, challenges, and future directions. JAAOS Global Research & Reviews. 2026 Jan;10(1):e25.00236. https://pubmed.ncbi.nlm.nih.gov/41490200/
  5. Tokura Y, Nakayama Y, Fukada S, Nara N, Yamamoto H, Matsuda R, Hara T. Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts. Journal of Biochemistry. 2011;149(1):43-48. https://pubmed.ncbi.nlm.nih.gov/20880960/
  6. Treadwell T, Kleinman HK, Crockford D, Hardy MA, Guarnera GT, Goldstein AL. The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Annals of the New York Academy of Sciences. 2012;1270:37-44. https://pubmed.ncbi.nlm.nih.gov/23050815/
  7. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323-333. https://link.springer.com/article/10.1007/s00109-016-1488-y
  8. Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific Reports. 2020;10:17078. https://pubmed.ncbi.nlm.nih.gov/33051481/
  9. Seiwerth S, Brcic L, Batelja Vuletic L, Kolenc D, Aralica G, Misic M, Zenko A, Drmic D, Rucman R, Sikiric P. BPC 157 and blood vessels. Current Pharmaceutical Design. 2014;20(7):1121-1125. https://pubmed.ncbi.nlm.nih.gov/23782145/
  10. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine. 2025 Dec;18(12):611-619. https://pubmed.ncbi.nlm.nih.gov/40789979/
  11. Sikiric P, Seiwerth S, Skrtic A, Staresinic M, et al. BPC 157 therapy: targeting angiogenesis and nitric oxide's cytotoxic and damaging actions, but maintaining, promoting, or recovering their essential protective functions. Pharmaceuticals (Basel). 2025;18(10):1450. https://pubmed.ncbi.nlm.nih.gov/41155565/